2026-04-14T02:13:59Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1743742025-12-05T12:10:08Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Ribera, Josep Maria author Morgades, Mireia author Montesinos, Pau author Tormo, Mar author Martínez Carballeira, Daniel author González Campos, José author Gil, Cristina author Barba, Pere author García Boyero, Raimundo author Coll, Rosa author Pedreño, María author Ribera, Jordi author Mercadal, Santiago author Vives, Susana author Novo, Andrés author Genescà, Eulàlia author Hernández Rivas, Jesús María author Bergua, Juan author Amigo, María Luz author Vall Llovera, Ferran author Martínez Sánchez, Pilar author Calbacho, María author García Cadenas, Irene author Garcia Guiñon, Antonio author Sánchez Sánchez, María José author Cervera, Marta author Feliu, Evarist author Orfao, Alberto author PETHEMA Group author 2021-02-26T08:54:27Z 2021-02-26T08:54:27Z 2020-04-01 2021-02-16T12:17:09Z Background: Pediatric-based or -inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL). Methods: This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15-30 years with standard-risk (SR) ALL. Results: From 2008 to 2018, 89 patients (38 adolescents [15-18 years] and 51 young adults [YA, 19-30 years], median age: 20 [15-29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%. Twenty-two patients were transferred to a high-risk (HR) protocol because of poor marrow response on day 14 (n = 20) or high-level of end-induction minimal residual response (MRD ≥ 0.25%, n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%-47%), with significant differences between adolescents and YA: 13% (4%-28%) vs 52% (34%-67%), P = .012. No treatment-related mortality was observed in 66/66 patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The estimated 5-year overall survival (OS) was 74% (95%CI: 63%-85%), with significantly higher rates for adolescents vs YA: 87% (95%CI: 74%-100%) vs 63% (46%-80%), P = .021. Although CIR or OS were lower in patients who were transferred to a HR trial, the differences were not statistically significant (CIR: 34% [21%-47%] vs 37% [14%-61%]; OS: 78% [66%-90%] vs 61% [31%;91%]). Conclusion: A full pediatric trial is feasible and effective for AYA with Ph-neg, SR-ALL, with better results for adolescents than for YA. Outcome of patients with poor early response rescued with a HR trial was not significantly inferior. Leucèmia limfocítica crònica Adolescents Chronic lymphocytic leukemia Teenagers A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial